Daiichi reports Phase I/II data for DMD candidate

Daiichi Sankyo Co. Ltd. (Tokyo:4568) said once-weekly subcutaneous DS-5141 missed the primary endpoint of improving dystrophin protein expression in muscle tissue at week 12 compared with baseline an open-label, Japanese Phase I/II trial to treat Duchenne muscular dystrophy (DMD). The company said it plans to start "as soon as possible" a 48-week extension study in the trial’s same seven patients to evaluate the effect of longer dosing on the primary endpoint.

Daiichi said DS-5141 met the secondary endpoint of improving production of exon 45-skipped dystrophin mRNA in muscle tissue at week 12 compared with baseline. No safety concerns were reported...